Adicet Bio: Prula-cel Shows Positive SLE/LN Phase 1 Data

Adicet Bio announced positive safety and efficacy data from its Prula-cel Phase 1 study in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN). The data showed high rates of immunosuppressant-free responses, with 50% of lupus nephritis patients achieving complete renal response and 54% of evaluable patients achieving DORIS remission at 12 months. Prula-cel demonstrated a favorable safety profile with no severe cytokine release syndrome (CRS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or immune effector cell-associated neurotoxicity syndrome (ICANS). The company plans to initiate pivotal study start-up activities in Q4 2026.